ArticleBreast cancer research and treatment2020

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.

Kaitlyn J Andreano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.